IceCure Medical (ICCM) said Monday that it has received a notice of allowance from the China National Intellectual Property Administration for its cryogenic system connector invention.
The notice follows grants for the same patent in the US, Europe, and Japan, the company said.
The company said its novel cryogenic pump is submersible in liquid nitrogen and is designed to be used for multiple procedures or longer duration procedures without the need to refill.
IceCure said it develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors by freezing, as an alternative to surgical tumor removal.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.